Lv4
418 积分 2021-08-02 加入
RIPK2 inhibitors for disease therapy: Current status and perspectives
15小时前
待确认
The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges
1天前
已完结
What influences the activity of Degrader−Antibody conjugates (DACs)
1天前
已完结
Molecular glue degraders: exciting opportunities for novel drug discovery
2天前
已完结
The application of PROTACs in immune-inflammation diseases
2天前
已完结
Development of PROTAC Degrader Drugs for Cancer
2天前
已完结
Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review
3天前
已完结
Protein degraders push into novel target space
11天前
已完结
PROTAC protein degraders to drug the undruggable enter phase 3 trials
11天前
已完结
Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes
12天前
已完结
皖公网安备34019202002308
